A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd; Pfizer
- 09 Apr 2018 Status changed from recruiting to completed.
- 03 Apr 2018 This trial was completed in Germany (End date: 2018-03-20), according to European Clinical Trials Database.
- 23 Feb 2018 This trial was completed in Spain, according to European Clinical Trials Database.